Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Eur Urol. 2014 Jun 30;67(2):233–238. doi: 10.1016/j.eururo.2014.06.010

Fig. 2.

Fig. 2

Time to discontinuation of active surveillance by reason for discontinuation (biopsy/prostate-specific antigen progression, patient preference, or other reasons). Dx = diagnosis; PSA = prostate-specific antigen.